Frutarom Health will lead a concerted effort to strengthen its phytopharmaceutical business in 2017, following last year’s acquisition of Extrakt Chemie.
Frutarom’s range of plant-based medicinals includes EflaPharm, the range of pharma-grade herbal extracts, produced according to GMP guidelines. The botanical extracts are suitable as active ingredients for the global pharmaceutical market, which is estimated to be worth between €750 million and €850 million.
It focus on its phytopharmaceutical business after the 2016 acquisition of Hannover-based Extrakt Chemie, which complemented previous additions to Frutarom’s medicinal ingredients offering in Europe, such as that of Slovenia’s Vitiva.
Frutarom Health plans to grow its Extrakt Chemie acquisition through globalisation, utilising its international sales network. Frutarom has initiated investments in the company’s production site to increase capacity and fulfil demand pharmaceutical ingredients.
The company has implemented a third production shift, to be followed by an expansion of the site (including production and office areas) to establish Extrakt Chemie as a hub for Frutarom’s pharmaceutical expertise.
Frutarom BU Health pharma business manager Barbara Bradl said: “With the acquisition of Extrakt Chemie, plus the directed site investments in people, equipment, manufacturing buildings and new offices, and the new combined team of highly experienced pharmaceutical experts, we feel Frutarom can bring significant value to the phytopharmaceuticals market.
“Adding the legacy Extrakt Chemie portfolio to the already strong EflaPharm line of Frutarom Health products creates new market opportunities for both the companies and the consumers. Growing this business is a key element of our business unit health strategy.”
© FoodBev Media Ltd 2024